Cargando…
Corrigendum to “Rational approach to drug discovery for human schistosomiasis” [Int. J. Parasitol. Drugs Drug Resist. 16 (2021) 140–147]
Autores principales: | LoVerde, Philip T., Alwan, Sevan N., Taylor, Alexander B., Rhodes, Jayce, Chevalier, Frédéric D., Anderson, Timothy Jc, McHardy, Stanton F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254624/ https://www.ncbi.nlm.nih.gov/pubmed/35067439 http://dx.doi.org/10.1016/j.ijpddr.2022.01.003 |
Ejemplares similares
-
Rational approach to drug discovery for human schistosomiasis
por: LoVerde, Philip T., et al.
Publicado: (2021) -
Oxamniquine derivatives overcome Praziquantel treatment limitations for Schistosomiasis
por: Alwan, Sevan N., et al.
Publicado: (2023) -
Addressing the oxamniquine in vitro-in vivo paradox to facilitate a new generation of anti-schistosome treatments
por: Toth, Katalin, et al.
Publicado: (2023) -
Corrigendum to “Therapeutic effect of ursolic acid in experimental visceral leishmaniasis” [Int. J. Parasitol. Drugs Drug Resist. 7 (2017) 1–11]
por: Jesus, Jessica A., et al.
Publicado: (2017) -
Corrigendum to “Genetic diversity of next generation antimalarial targets: A baseline for drug resistance surveillance programmes” [Int. J. Parasitol. Drugs and Drug Resist. 7 (2017) 174–180]
por: Gomes, Ana Rita, et al.
Publicado: (2017)